AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing